UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934

~~March~~July 158, 2011

________________

Crucell NV
(Exact name of registrant as specified in its charter)

P.O. Box 2048 Archimedesweg 4 2333 CN Leiden The Netherlands
(Address of principal executive offices)

000-30962
(Commission File Number)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F [ x ] Form 40-F [ ]

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [ ] No [ x ]

~~PRESS~~Crucell ~~RELEASE~~Discovers Important New Antibody Against Influenza A

Leiden, The Netherlands (July 7, 2011) - Dutch biopharmaceutical company Crucell ~~Intends~~N.V. and The Scripps Research Institute today published an article in the world's leading journal of original scientific research Science describing Crucell's novel anti-influenza antibody CR8020 and how it neutralizes group 2 influenza A viruses. Attempts to ~~Delist~~isolate ~~Ordinary~~broadly ~~Shares~~neutralizing onantibodies ~~NYSE Euronext~~against group 2 viruses have not been previously described. The broad neutralizing ability of the CR8020 makes it a potentially groundbreaking therapy against seasonal and pandemic flu.

~~Leiden,~~"Influenza ~~the~~is ~~Netherlands~~an ~~(March~~elusive 15enemy" said Jaap Goudsmit, ~~2011)~~Chief –Scientific ~~Dutch biopharmaceutical~~Officer ~~company~~at Crucell N.V. ~~(NYSE~~"The ~~Euronext,~~need ~~NASDAQ:~~for ~~CRXL;~~innovative ~~Swiss Exchange:~~approaches ~~CRX)~~to ~~today~~the ~~announced~~control ~~that~~of itseasonal ~~has~~influenza ~~obtained~~is ~~the~~highlighted ~~approval~~by ofits ~~Euronext Amsterdam~~death ~~N.V.~~toll to- ~~terminate~~estimated ~~the~~at ~~listing~~500,000 ofannually. ~~its~~Having ~~ordinary~~successfully ~~shares~~discovered ~~(Ordinary Shares)~~these onantibodies, ~~NYSE~~Crucell ~~Euronext~~is indetermined ~~Amsterdam~~to ~~(NYSE~~develop ~~Euronext)~~an antibody therapy for flu."

In February 2009, Crucell and The ~~termination~~Scripps ofResearch Institute published a paper in Science, reporting the ~~listing~~discovery of ~~Ordinary~~a ~~Shares~~panel onof ~~NYSE Euronext~~human ~~was~~monoclonal ~~approved~~antibodies byshowing ~~Euronext~~neutralizing ~~Amsterdam~~activity ~~N.V.~~against ~~and~~almost ~~will~~all ~~occur~~influenza onA 12group ~~April 2011~~1 viruses. The ~~last~~most ~~trading~~potent ~~day~~of ~~will~~these beantibodies, 11called ~~April~~CR6261, ~~2011~~prevents or cures influenza, in animal tests, to deadly levels of the H5N1 and H1N1 viruses.

AsIn ofthis ~~the~~new ~~time~~study, ofCrucell ~~delisting~~reports ~~from~~that, ~~NYSE~~by ~~Euronext~~recognizing a novel conserved epitope in the hemagglutinin stem, the ~~following~~ ~~codes~~antibody ~~will~~CR8020 noshows ~~longer~~broad beneutralizing ~~applicable~~activity toagainst ~~Crucell~~most ~~N.V.~~influenza ~~(Crucell):~~A ~~symbol “CRXL”:~~group ~~Euronext~~2 ~~code~~viruses, ~~NL0000358562~~including the H3N2 and H7N7 viruses, ~~ISIN:~~which ~~NL0000358562~~cause severe human infection.

Crucell ~~intends~~believes tothat ~~delist~~a ~~the~~combination ~~Ordinary~~of ~~Shares~~these ~~from~~two ~~the Swiss~~antibodies ~~Exchange~~may ~~(SIX)~~be ~~simultaneously~~sufficient to neutralize most influenza A subtypes and, with that, enable the ~~delisting~~development ~~from~~of ~~NYSE~~a ~~Euronext~~universal flu vaccine and a broad spectrum of antibody therapies.

AsAttempts ~~previously announced on 8 March 2011,~~ to ~~effect~~isolate ~~the delisting~~broadly ofneutralizing ~~the~~antibodies ~~American~~against ~~Depositary~~group ~~Shares~~2 ~~(ADSs)~~viruses ~~from~~have ~~the~~not ~~NASDAQ~~been ~~Global Market~~previously ~~Select~~described. ~~(NASDAQ)~~Antibodies, ~~Crucell~~such ~~intends~~as toCR6261 ~~file a Form 25 with the U.S. Securities~~ and ~~Exchange~~CR8020, ~~Commission~~may ~~(SEC).~~protect ~~Crucell~~against ~~intends~~essentially toall ~~file~~influenza aA ~~Form~~viruses ~~15F with the SEC to deregister~~ and ~~terminate~~would ~~its~~have ~~reporting~~undisputed ~~obligations~~benefits ~~under~~for ~~the U.S.~~high-risk ~~Securities Exchange Act of 1934~~groups, such as ~~amended. The filing of~~ the ~~Form~~elderly ~~15F will~~and ~~precede~~immunocompromised, ~~the~~and ~~delisting~~for ofsevere, ~~the~~life-threatening ~~Ordinary~~influenza ~~Shares from NYSE Euronext and SIX~~infections.

~~Crucell~~Influenza ~~reserves~~and ~~the~~related ~~right~~medical tocomplications ~~delay~~result orin ~~withdraw~~an ~~for~~estimated ~~any reason~~number ~~the~~of ~~filing~~500,000 ofannual ~~the~~deaths ~~Form~~worldwide. 25Every ~~and~~year ~~Form~~more ~~15F~~than or200,000 people in the ~~delisting~~United onStates ~~NYSE~~are ~~Euronext~~ hospitalized from flu complications and~~/or~~ ~~SIX~~about 36,000 people die from flu[1].

~~About~~Currently, ~~Crucell~~two main countermeasures are used against flu. Antivirals have been widely used and proven to be quite effective. However, resistance to these antivirals has reduced their effectiveness and mutations are widespread.

~~Crucell~~Vaccination ~~N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX)~~ is athe ~~global~~other ~~biopharmaceutical~~countermeasure. ~~company~~Each ~~focused~~year oncirculating ~~research~~strains ~~development, production~~of ~~and~~influenza ~~marketing~~virus ~~of vaccines~~subtypes, ~~proteins~~currently ~~and~~H1 ~~antibodies that prevent~~ and~~/or~~ ~~treat infectious diseases. In 2010 alone~~H3, ~~Crucell~~change ~~distributed more than 105 million vaccine doses in more than 100 countries around~~ the ~~world.~~composition ~~Crucell is one~~ of the ~~major~~viral ~~suppliers~~surface ofprotein ~~vaccines~~known toas ~~UNICEF~~hemagglutinin ~~and~~by ~~the developing world~~mutation. ~~Crucell~~ ~~was~~Consequently, ~~the~~if ~~first~~one ~~manufacturer~~has tohad ~~launch~~ a ~~fully-liquid~~vaccination ~~pentavalent vaccine.~~against ~~Called~~influenza ~~Quinvaxem®,~~ this ~~innovative~~year, ~~combination~~the ~~vaccine~~antibodies ~~protects~~produced ~~against~~by ~~five~~the ~~important~~immune ~~childhood diseases.~~system ~~Over~~will ~~180~~most ~~million~~likely ~~doses~~not ~~have~~protect ~~been~~against ~~sold~~next ~~since~~years' ~~its launch in 2006 in more than 50 GAVI countries~~flu. ~~With~~If ~~this~~an ~~innovation,~~antibody ~~Crucell~~was ~~has~~able ~~become~~to arecognize ~~major partner~~an ininvariable ~~protecting~~structure ~~children~~ in ~~developing~~the ~~countries.~~hemagglutinin ~~Other products in Crucell’s core portfolio include a vaccine against hepatitis B and a virosomeadjuvanted vaccine against influenza. Crucell also markets travel vaccines~~protein, such as an ~~oral~~ ~~anti-typhoid~~antibody ~~vaccine,~~could anbe ~~oral~~applied ~~cholera~~for ~~vaccine and~~ the ~~only~~prevention ~~aluminum-free hepatitis~~and Atherapy ~~vaccine~~of oninfluenza ~~the~~caused ~~market.~~by ~~Crucell has~~ a ~~broad~~wide ~~development~~variety ~~pipeline, with~~of ~~several~~flu ~~product candidates based on its unique PER~~strains.~~C6® production~~ ~~technology. Crucell licenses its PER.C6® technology and other technologies to the~~

~~biopharmaceutical~~The ~~industry.~~unique ~~Important~~property ~~partners~~of ~~and licensees~~the ~~include~~Crucell ~~Johnson~~antibodies &appears ~~Johnson,~~to ~~DSM~~be ~~Biologics,~~related ~~sanofi-aventis, Novartis,~~to ~~Pfizer/Wyeth,~~its ~~GSK,~~mechanism ~~CSL~~of ~~and~~action. ~~Merck~~The &paper ~~Co.~~published ~~Crucell~~in isScience ~~headquartered in~~entitled ~~Leiden,~~"A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses" shows the ~~Netherlands,~~isolation and characterization of a human monoclonal antibody CR8020 with ~~offices~~broad inneutralizing ~~China,~~activity ~~Indonesia,~~against ~~Italy,~~most ~~Korea, Malaysia,~~group ~~Spain,~~2 ~~Sweden~~viruses, ~~Switzerland,~~including UKH3N2 and H7N7, ~~the~~which ~~USA~~sporadically ~~and~~cross ~~Vietnam.~~from ~~Crucell~~birds ~~employs over~~into ~~1300~~humans ~~people.~~and ~~For~~have ~~more~~the ~~information,~~potential ~~please~~to ~~visit~~develop ~~www~~into a future pandemic.~~crucell.com.~~

~~Forward-looking~~"Influenza ~~statements~~A viruses responsible for human pandemics have arisen from both group 1 and group 2 viruses." says Dr Robert Friesen, Crucell's Vice President Preclinical and Clinical Research. "Therefore these results are a revolutionary discovery for the potential development of an effective therapy of, and prevention against, seasonal and pandemic influenza".

~~This~~The ~~press~~results ~~release contains forward-looking statements that involve inherent risks and uncertainties. We have identified a number~~ of ~~important~~ ~~factors~~this ~~that~~study ~~may~~will ~~cause~~be ~~actual~~presented ~~results~~by toDr ~~differ~~Robert ~~materially~~Friesen ~~from~~at ~~those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with~~ the US7th ~~Securities~~Annual ~~and Exchange~~European ~~Commission~~Antibody onCongress ~~April~~taking 7,place ~~2010,~~from inNovember ~~the~~29th ~~section~~till ~~entitled~~December ~~‘Risk~~1st ~~Factors’ and~~ in ~~our second quarter 2010 financial results~~Geneva, ~~as filed with the Securities and Exchange Commission on August 17, 2010 in the section entitled ‘Risk Paragraph’~~Switzerland. ~~The Company prepares its financial statements under International Financial Reporting Standards (IFRS).~~

For both studies, Crucell collaborated with the Scripps Research Institute in California, USA, which is a world leader in this type of molecular-level research, the department of microbiology of the Univeristy of Hong Kong in Hong Kong, and the Central Veterinary Institute of the University of Wageningen in Lelystad, The Netherlands.

This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272200900060C.

[1] Source: Centers for Disease Control and Prevention.

Article reference: A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses. Authors: Damian C. Ekiert,1# Robert H. E. Friesen,2# Gira Bhabha,1 Ted Kwaks,2 Mandy Jongeneelen,2 Wenli Yu,1 Carla Ophorst,2 Freek Cox,2 Hans J.W.M. Korse,2 Boerries Brandenburg,2 Ronald Vogels,2 Just P.J. Brakenhoff,2 Ronald Kompier,2 Martin H. Koldijk,2 Lisette A.H.M. Cornelissen,3 Leo L. M. Poon,4 Malik Peiris,4 Wouter Koudstaal,2* Ian A. Wilson,1,5 and Jaap Goudsmit2

1 Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA; 2 Crucell Holland BV, Archimedesweg 4-6, 2301 CA Leiden, The Netherlands; 3 Central Veterinary Institute, Wageningen University, Lelystad, the Netherlands; 4 Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China; 5 The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. # These authors contributed equally to this work.

About Crucell
Crucell N.V. is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. In 2010 alone, Crucell distributed more than 105 million vaccine doses in more than 100 countries around the world. Crucell is one of the major suppliers of vaccines to UNICEF and the developing world. Crucell was the first manufacturer to launch a fully-liquid pentavalent vaccine. Called Quinvaxem®, this innovative combination vaccine protects against five important childhood diseases. Over 200 million doses have been sold since its launch in 2006 in more than 50 GAVI countries. With this innovation, Crucell has become a major partner in protecting children in developing countries. Other products in Crucell's core portfolio include a vaccine against hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as an oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. Crucell has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. Crucell licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Pfizer/Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with offices in China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, UK, the USA and Vietnam. Crucell employs over 1300 people.

Johnson & Johnson completed the tender offer for Crucell N.V. (Crucell) on 22nd February 2011 and declared the offer unconditional. As a result, Crucell will now operate as the center for vaccines within the Johnson & Johnson pharmaceuticals group.

For more information, please visit www.crucell.com.

Forward-looking statements
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Crucell N.V. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Crucell N.V. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)

For further information please contact:

Crucell: Oya Yavuz Vice President Corporate Communications Tel. +31 (0)71 519 7064 communications@crucell.com www.crucell.com

Vice President Corporate Communications & Investor Relations

Tel. +31 (0)71 519 7064

ir@crucell.com

www.crucell.com

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Crucell NV (Registrant) ~~March~~July 158, 2011 (Date) /s/ OYA YAVUZ Oya Yavuz Vice President Corporate Communications and Investor Relations

Filing Compare · CRUCELL NV